
Akebia Therapeutics AKBA
$ 0.39
-7.14%
Akebia Therapeutics Book Value | AKBA
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Akebia Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.6 M | -49.2 M | -30.6 M | 5.23 M | 74 M | 248 M | 395 M | 636 M | 119 M | 68.1 M | 131 M | 104 M | 30.8 M | -2.68 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 636 M | -49.2 M | 126 M |
Quarterly Book Value Akebia Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.4 M | 25 M | 27.4 M | 32.6 M | 41.6 M | 29.2 M | 24.6 M | -49.2 M | -50.4 M | -33.8 M | -27.3 M | -30.6 M | -39.4 M | -26.8 M | -19.1 M | 5.23 M | 8.26 M | 58.9 M | 22.6 M | 74 M | 137 M | 175 M | 214 M | 248 M | 318 M | 370 M | 396 M | 395 M | 468 M | 519 M | 566 M | 636 M | 143 M | 166 M | 197 M | 123 M | 99.9 M | 57 M | 30.6 M | 68.1 M | 101 M | 133 M | 168 M | 131 M | 145 M | 150 M | 94.6 M | 104 M | 114 M | 122 M | 128 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 636 M | -50.4 M | 126 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Collegium Pharmaceutical
COLL
|
302 M | $ 24.73 | -1.9 % | $ 783 M | ||
|
Evogene Ltd.
EVGN
|
12 M | $ 0.32 | 1.02 % | $ 2.52 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
148 M | $ 2.05 | -15.81 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
61 M | $ 76.99 | 0.03 % | $ 997 M | ||
|
Curis
CRIS
|
5.46 M | $ 0.44 | -6.31 % | $ 5.79 M | ||
|
CorMedix
CRMD
|
405 M | $ 5.25 | 4.23 % | $ 378 K | ||
|
Larimar Therapeutics
LRMR
|
78.1 M | $ 3.07 | -4.66 % | $ 255 M | ||
|
Champions Oncology
CSBR
|
4.07 M | $ 4.34 | -1.36 % | $ 60 M | ||
|
Mesoblast Limited
MESO
|
597 M | $ 10.9 | -2.5 % | $ 13.2 B | ||
|
Mirum Pharmaceuticals
MIRM
|
315 M | $ 96.15 | 0.67 % | $ 4.83 B | ||
|
MannKind Corporation
MNKD
|
-51 M | $ 3.85 | -2.66 % | $ 1.18 B | ||
|
Dyadic International
DYAI
|
1.23 M | $ 0.29 | -6.53 % | $ 10.5 M | ||
|
Merck & Co.
MRK
|
137 B | $ 133.34 | 0.4 % | $ 334 B | ||
|
Moderna
MRNA
|
8.65 B | $ 195.25 | -2.05 % | $ 76 B | ||
|
NuCana plc
NCNA
|
24.3 M | $ 0.75 | 4.39 % | $ 8.42 B | ||
|
Novartis AG
NVS
|
46.5 B | $ 150.51 | -0.47 % | $ 292 B | ||
|
Puma Biotechnology
PBYI
|
130 M | $ 7.05 | -1.05 % | $ 353 M | ||
|
Fulcrum Therapeutics
FULC
|
311 M | $ 3.69 | -0.67 % | $ 281 M | ||
|
PDS Biotechnology Corporation
PDSB
|
9.25 M | $ 0.79 | -2.58 % | $ 36.6 M | ||
|
Geron Corporation
GERN
|
226 M | $ 0.87 | -4.76 % | $ 580 M | ||
|
Pharming Group N.V.
PHAR
|
149 M | $ 11.54 | -5.18 % | $ 7.95 B | ||
|
Phathom Pharmaceuticals
PHAT
|
-438 M | $ 4.65 | -8.46 % | $ 339 M | ||
|
Genmab A/S
GMAB
|
36.7 B | $ 50.36 | -1.93 % | $ 3.26 B | ||
|
Gossamer Bio
GOSS
|
-123 M | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Grifols, S.A.
GRFS
|
8.61 B | $ 8.14 | -0.73 % | $ 5.53 B | ||
|
Liquidia Corporation
LQDA
|
44.7 M | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
GlaxoSmithKline plc
GSK
|
16 B | $ 47.8 | -0.05 % | $ 194 B | ||
|
MediciNova
MNOV
|
41.6 M | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
-205 M | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
3.59 M | $ 1.24 | -12.34 % | $ 4.53 B | ||
|
InflaRx N.V.
IFRX
|
41.6 M | $ 1.05 | -3.67 % | $ 70.7 M | ||
|
Immunome
IMNM
|
634 M | $ 15.69 | -5.54 % | $ 1.37 B | ||
|
Immuron Limited
IMRN
|
8.07 M | $ 0.9 | 5.87 % | $ 208 M | ||
|
Incyte Corporation
INCY
|
5.17 B | $ 114.5 | -1.19 % | $ 22.4 B | ||
|
INmune Bio
INMB
|
23.5 M | $ 0.82 | -8.41 % | $ 20.3 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
337 B | $ 14.88 | 0.24 % | $ 12.4 B | ||
|
Regeneron Pharmaceuticals
REGN
|
31.3 B | $ 920.38 | -0.22 % | $ 96.3 B | ||
|
Ionis Pharmaceuticals
IONS
|
489 M | $ 26.58 | -2.37 % | $ 4.25 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 1.06 | -10.92 % | $ 48.4 M | ||
|
Ironwood Pharmaceuticals
IRWD
|
397 M | $ 4.68 | -0.53 % | $ 757 M | ||
|
Kala Pharmaceuticals
KALA
|
7 M | $ 2.73 | -9.61 % | $ 22.2 M | ||
|
Intellia Therapeutics
NTLA
|
671 M | $ 10.02 | 5.24 % | $ 1.09 B | ||
|
Adagene
ADAG
|
51.9 M | $ 1.8 | -10.56 % | $ 106 M | ||
|
Denali Therapeutics
DNLI
|
1.01 B | $ 18.43 | 1.29 % | $ 3.18 B | ||
|
Pfizer
PFE
|
86.8 B | $ 27.4 | -0.62 % | $ 156 B | ||
|
Amarin Corporation plc
AMRN
|
459 M | $ 10.56 | -6.26 % | $ 4.38 B | ||
|
ImmuCell Corporation
ICCC
|
27.1 M | $ 11.08 | -0.81 % | $ 100 M | ||
|
Editas Medicine
EDIT
|
27.3 M | $ 1.63 | -4.68 % | $ 145 M | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
568 M | $ 93.83 | 0.32 % | $ 6.96 B | ||
|
Agios Pharmaceuticals
AGIO
|
1.19 B | $ 27.54 | -4.24 % | $ 1.6 B |